The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

MDS 2020 | Prognosis and treatment in high-risk MDS

Name: Prognosis and treatment in high-risk MDS
Uploaded: 2020-03-05T00:00:00.000Z
Duration: 1 min 25 s
Description: Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses the unmet need for novel treatments in high-risk myelodysplastic syndromes (MDS), with reference to the advantages and disadvantages of using azacitidine. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

Drorit Merkel • 5 Mar 2020

MDS 2020

Myelodysplastic Syndromes Azacitidine

Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses the unmet need for novel treatments in high-risk myelodysplastic syndromes (MDS), with reference to the advantages and disadvantages of using azacitidine. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.